SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|Item 5.02.|| |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 27, 2023, Mr. Brian Silver informed TScan Therapeutics, Inc. (the “Company”) of his intent to step down from his roles as Chief Financial Officer and Treasurer of the Company, effective July 21, 2023. Mr. Silver’s resignation from the Company is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company plans to conduct a search for a successor chief financial officer.
|Item 7.01.|| |
Regulation FD Disclosure.
On June 29, 2023, the Company issued a press release announcing the resignation of Mr. Silver from his position as Chief Financial Officer and other Company updates. A copy of the press release is attached hereto as Exhibit 99.1.
The information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
|Item 9.01.|| |
The following exhibits are filed as part of this report:
|99.1||Press release, dated June 29, 2023.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|TScan Therapeutics, Inc.|
|Date: June 29, 2023||By:|
|Chief Executive Officer|
TScan Therapeutics Announces Transition of Chief Financial Officer
WALTHAM, Mass., June 29, 2023 TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-Ts) for the treatment of patients with cancer, today announced that its Chief Financial Officer, Brian M. Silver, J.D., will be leaving the Company, effective July 21, 2023, to pursue a new opportunity at a leading advisory firm based in New York, where he lives with his family. Brian will continue to be available to provide strategic advice for the Company. The Company has initiated a search for a successor chief financial officer.
We extend our sincere thanks to Brian for his important contributions since joining the Company and wish him well in his new endeavor, said Gavin MacBeath, Ph.D., Chief Executive Officer. Brians extensive experience in biotechnology executive leadership roles has been crucial in ensuring the financial strength of the Company and has allowed him to contribute to the advancement of our strategy and clinical programs. We are pleased that Brian will be able to continue his relationship with TScan by providing strategic advice, as his expertise, knowledge, vision, energy, and passion have proven invaluable to our Company.
It has been a privilege working initially as a board member and then as an executive with my colleagues at TScan. I am proud to have helped TScan grow from a preclinical platform company to a fully integrated research, development and manufacturing organization working to improve the lives of patients with cancer and autoimmune disease through the development of advanced cell therapies. I look forward to continuing to provide strategic input to TScan in the future, said Mr. Silver. With the proceeds of our convertible note with K2, the Amgen research partnership and our follow-on financing, I am confident that TScan has the financial capability to execute on our significant clinical milestones into 2026.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The Companys lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, the Companys repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplexed TCR-T therapies for patients with a variety of solid tumors.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding the Companys plans, progress, and timing relating to the Companys solid tumor programs and the presentation of data, the Companys current and future research and development plans or expectations, the structure, timing and success of the Companys planned preclinical development, submission of INDs, and clinical trials, the potential benefits of any of the
Companys proprietary platforms, multiplexing, or current or future product candidates in treating patients, and the Companys goals and strategy. TScan intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, may, might, will, objective, intend, should, could, can, would, expect, believe, anticipate, project, target, design, estimate, predict, potential, plan, on track, or similar expressions or the negative of those terms. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. The express or implied forward-looking statements included in this release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: the beneficial characteristics, safety, efficacy, therapeutic effects and potential advantages of TScans TCR-T therapy candidates; TScans expectations regarding its preclinical studies being predictive of clinical trial results; the timing of the initiation, progress and expected results of TScans preclinical studies, clinical trials and its research and development programs; TScans plans relating to developing and commercializing its TCR-T therapy candidates, if approved, including sales strategy; estimates of the size of the addressable market for TScans TCR-T therapy candidates; TScans manufacturing capabilities and the scalable nature of its manufacturing process; TScans estimates regarding expenses, future milestone payments and revenue, capital requirements and needs for additional financing; TScans expectations regarding competition; TScans anticipated growth strategies; TScans ability to attract or retain key personnel; TScans ability to establish and maintain development partnerships and collaborations; TScans expectations regarding federal, state and foreign regulatory requirements; TScans ability to obtain and maintain intellectual property protection for its proprietary platform technology and our product candidates; the sufficiency of TScans existing capital resources to fund its future operating expenses and capital expenditure requirements; and the effect of the COVID-19 pandemic, including mitigation efforts and political, economic, legal and social effects, on any of the foregoing or other aspects of TScans business or operations; and other factors that are described in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of TScans most recent Annual Report on Form 10-K and any other filings that TScan has made or may make with the SEC in the future. Any forward-looking statements contained in this release represent TScans views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, TScan explicitly disclaims any obligation to update any forward-looking statements.
TScan Therapeutics, Inc.
VP, Investor Relations
LifeSci Advisors, LLC